Pharmaceutical major, Zydus Cadila is working big time on the global biosimilars market that is predicted to be approximately US $35.7 billion by 2025. The company has 21 biosimilars, either in its portfolio or pipeline including IFNα-2b, PEG-IFN, PTH , G-CSF, PEGG-CSF, EPO, Adalimumab, Trastuzumab, Bevacizumab, Rituximab, Peg-Asparagase and r-FSH.

As a key milestone, Zydus India’s formulation business crossed US $500 million to contribute around 27% of overall revenues. The company has raked in US $2 billion revenue during FY 2020 and features among the top three in respiratory, pain, gynecology, nephrology and oncology.

The approved product range of the company holds the value of US $2.3 billion and filed products awaiting approval are worth US $6 billion. At the same time, its under development products form the market potential of US $2.5 billion. A total of 15 filed products awaiting approval constitutes a US $6 billion market, out of which seven are complex and eight are regular. The 37 products in the under-development category, out of which 14 are complex and 23 are regular which have a market worth US $19 billion. 

Aiming to achieve excellence in manufacturing and quality operations through the use of digital and data analytics tools for effective decision making, Zydus has reached cumulative savings of over US $80 million.

The company is also aiming to reduce in-sourcing from China. It is looking at reducing China sourcing dependency from 46% to 35% in API manufacturing during the next two years. Within the formulation business, the company aims to reduce China sourcing dependency from 22% to 17% in the next one year.

Having spent 70 years in business excellence, Zydus Cadila has a combined turnover of US $6.92 billion and a market cap of  around US$155 million. The company has spent US $155 million on R&D during FY 2020. It has the largest integrated biologics and vaccines portfolio across India.

Tapping mega global opportunities

The near to mid-term strategy of Zydus includes the creation of two distinct sets of portfolios catering to Indian and European markets. The company is also developing a portfolio of complex generic injectable products, including drug-device combination products for the United States market. It already has 108 products in the US injectable portfolio.

The company’s well-balanced portfolio of high-value products across the various stages of development indicates the prospective business growth opportunity that lies ahead of it. The portfolio targets 15 products worth around US $14 billion and 4 products marketed in India's global vaccines market worth around US $60 billion size by 2026.

As per the company, it will continue to extend the coverage of around 63% of global business with multiple vendors and work closely with vendors for long-term visibility and strategic partnership. 

Zydus has 337 approved or commercialized products worth US $66 billion and 254 products Filed/Under development worth US $119 billion addressable market size. The company’s global business has a strong presence in the regulated markets of the US, Europe (France and Spain) and in the high profile markets of Latin America and South Africa. It is also present in a big way in 25 other emerging markets worldwide. It aims to have a select play in regulated markets with an objective to create a strong franchise in the oncology segment where it already has 29 products worth US $27 billion. 

Among the key milestones achieved by the company so far are over 99% supply chain efficiency (product availability) in the last 3 years besides addressing supply chain vulnerability by extending safety coverage of key components with a higher risk of supply. It has secured 38% of global business with multiple vendors and with key vendors on strategic partnership and giving long term visibility.